Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure
Simone Langforda, §, Angele Gayet-Ageronb, §, Chris Duncombea, Thidarat Jupimaia, Apicha Mahanontharita, Sasisopin Kiertiburanakulc, Warangkana Munsakuld, Kiat Ruxrungthama, e, Bernard Hirschelb, Jintanat Ananworanich*, a, f, Staccato Study Group
Identifiers and Pagination:Year: 2008
First Page: 69
Last Page: 73
Publisher Id: TOVJ-2-69
Article History:Received Date: 13/6/2008
Revision Received Date: 23/9/2008
Acceptance Date: 24/9/2008
Electronic publication date: 16/10/2008
Collection year: 2008
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
In HIV patients who discontinue highly active antiretroviral therapy (HAART), the degree of HIV RNA suppression at the time of treatment interruption may predict success of re-treatment after the interruption (STI). A case-control substudy of the Staccato trial in Thailand included CD4-guided STI subjects with HIV RNA > 50 copies /ml (virological failure cases, n=11) and HIV RNA < 50 copies/ml (controls, n=22) after 12-24 weeks of HAART re-treatment following a median of 2 STI cycles. Controls were matched for age, gender and pre-ART CD4 count. HIV RNA with 5 copies/ml detection limit was determined on pre-virological failure samples. HIV RNA increased in cases compared to controls with each successive STI cycle (p-trend across time-points 0.004). The last HIV RNA below 50 copies/ml was significantly higher among cases compared to controls (p=.004). Measuring HIV RNA below 50 copies/ml may be useful in predicting virological failure to STI.